Application of wedelolactone in preparation of anti-pulmonary fibrosis drug

A technology of wedelolide and pulmonary fibrosis, which is applied in the field of chemical substances, and achieves the effects of wide practical value, clear pharmacological activity and low cost

Active Publication Date: 2014-05-28
CHINA PHARM UNIV
View PDF6 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there is no literature report that wedelolide has the effect of treating pulmonary fibrosis and its application in the treatment of pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of wedelolactone in preparation of anti-pulmonary fibrosis drug
  • Application of wedelolactone in preparation of anti-pulmonary fibrosis drug
  • Application of wedelolactone in preparation of anti-pulmonary fibrosis drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] 1. Preparation and structure confirmation of wedelolide

[0042] Eclipta prostrate L. is the dried aboveground part of Eclipta prostrate L., a plant in Compositae, purchased from Haozhou, Anhui. Dry the aerial part of the medicinal material Eclipta chinensis, reflux extract with 80% ethanol 10 times the volume of the crude drug for 3 times, each time for 2 hours, filter, combine the extracts, concentrate under reduced pressure to obtain 903 g of the total extract. Suspend the total extract in water, extract and remove fat-soluble components such as chlorophyll with equal amount of petroleum ether, concentrate the aqueous solution under reduced pressure, and extract with ethyl acetate and n-butanol in sequence to obtain ethyl acetate extract and n-butanol respectively Extract, ethyl acetate extract was subjected to silica gel column chromatography (CH 2 Cl 2 -MeOH-H 2 O (14:9:0.4, lower layer) elution), gel column chromatography (CHCl 3 -MeOH (1:1) elution) chromatog...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a drug application of a chemical substance wedelolactone for treatment of pulmonary fibrosis. The chemical substance wedelolactone is derived from a traditional Chinese medicine eclipta, and the structure is determined through spectral data; the wedelolactone can significantly improve the degree of model mouse lung tissue pulmonary fibrosis after intragastric administration, reduce NO (Nitrogen Oxide) and MDA (Methylene dioxyamphetamine) contents reflecting degree of lung injury, HYP (Hydroxyproline) content reflecting collagen deposition in the lung tissues, and cell factor TGF-beta 1 (Transforming Growth Factor) content causing pulmonary fibrosis, and inhibit human embryo lung fibroblast proliferation in vitro and HYP content of the human embryo lung fibroblast. In-vivo and in-vitro experiments show that wedelolactone can obviously improve bleomycin induced mouse pulmonary fibrosis, so that the wedelolactone can be taken as a novel drug for treating pulmonary fibrosis.

Description

technical field [0001] The invention relates to a new application of chemical substance wedelolide as a drug for treating pulmonary fibrosis. Background technique [0002] Pulmonary fibrosis is a progressive disease characterized by fibrosis and lung parenchymal remodeling. Pulmonary fibroblasts hyperproliferate, transdifferentiate into myofibroblasts, secrete a large amount of collagen and deposit matrix. There is no effective treatment. Bleomycin-induced pulmonary fibrosis animal model is the most commonly used. Pulmonary fibrosis induced by tracheal administration of bleomycin is a classic animal model for studying pulmonary fibrosis drugs at home and abroad. Bleomycin can cause inflammation and fibrosis of lung tissue in a short period of time, and increase pro-fibrotic markers such as TGF -Expression of β1, α-SMA, etc. Generally speaking, the bleomycin animal model begins to show fibrosis symptoms 9 days after modeling, and typical fibrosis symptoms appear on 21 days ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/37A61P11/00
Inventor 张朝凤许翔鸿张勉
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap